Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02639910
Title Study to Evaluate Efficacy and Safety of MOR208 With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi (COSMOS)
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors MorphoSys AG
Indications

chronic lymphocytic leukemia

chronic lymphocytic leukemia/small lymphocytic lymphoma

Therapies

Tafasitamab-cxix + Venetoclax

Idelalisib + Tafasitamab-cxix

Age Groups: senior | adult
Covered Countries USA | ITA | DEU | AUT

Facility Status City State Zip Country Details
Clinical Study Site Jacksonville Florida 32204 United States Details
Clinical Study Site Rochester Minnesota 55905 United States Details
Clinical Study Site Columbus Ohio 43210 United States Details
Clinical Study Site Graz 8036 Austria Details
Clinical Study Site Salzburg 5020 Austria Details
Clinical Study Site Wien 1090 Austria Details
Clinical Study Site Dresden 1307 Germany Details
Clinical Study Site Leipzig 4103 Germany Details
Clinical Study Site Muenchen 80804 Germany Details
Clinical Study Site Brescia 25123 Italy Details
Clinical Study Site Milano 20162 Italy Details
Clinical Study Site Gdansk 80952 Poland Details
Clinical Study Site Krakow 30510 Poland Details
Clinical Study Site Lublin 85094 Poland Details
Clinical Study Site Opole 45372 Poland Details
Clinical Study Site Bournemouth BH7 7DW United Kingdom Details
Clinical Study Site Leeds LS9 7TF United Kingdom Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field